FARESTON Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Fareston, and when can generic versions of Fareston launch?
Fareston is a drug marketed by Kyowa Kirin and is included in one NDA.
The generic ingredient in FARESTON is toremifene citrate. There are five drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the toremifene citrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Fareston
A generic version of FARESTON was approved as toremifene citrate by RISING on December 4th, 2018.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for FARESTON?
- What are the global sales for FARESTON?
- What is Average Wholesale Price for FARESTON?
Summary for FARESTON
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 70 |
| Clinical Trials: | 9 |
| Patent Applications: | 8,280 |
| Drug Prices: | Drug price information for FARESTON |
| What excipients (inactive ingredients) are in FARESTON? | FARESTON excipients list |
| DailyMed Link: | FARESTON at DailyMed |
Recent Clinical Trials for FARESTON
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Fred Hutchinson Cancer Research Center | Phase 4 |
| National Cancer Institute (NCI) | Phase 4 |
| Hebei Tumor Hospital | Phase 3 |
Pharmacology for FARESTON
| Drug Class | Estrogen Agonist/Antagonist |
| Mechanism of Action | Selective Estrogen Receptor Modulators |
US Patents and Regulatory Information for FARESTON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kyowa Kirin | FARESTON | toremifene citrate | TABLET;ORAL | 020497-001 | May 29, 1997 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for FARESTON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Kyowa Kirin | FARESTON | toremifene citrate | TABLET;ORAL | 020497-001 | May 29, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for FARESTON
See the table below for patents covering FARESTON around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Luxembourg | 88803 | ⤷ Sign Up | |
| Japan | H0419973 | ⤷ Sign Up | |
| Latvia | 5066 | Alkenatvasinajumu vai to salu iegusanas metode | ⤷ Sign Up |
| Hungary | 193536 | PROCESS FOR THE PRODUCTION OF NEW HYDROXY-ALKANE- AND ALKENE-TETRAHYDROFURAN- AND TETRAHYDROPYRAN-DERIVATIVES | ⤷ Sign Up |
| Hong Kong | 8389 | NOVEL TRI-PHENYL ALKANE AND ALKENE DERIVATIVES AND THEIR PREPARATION AND USE | ⤷ Sign Up |
| European Patent Office | 0095875 | NOVEL TRI-PHENYL ALKANE AND ALKENE DERIVATIVES AND THEIR PREPARATION AND USE | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for FARESTON
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0095875 | 96C0029 | Belgium | ⤷ Sign Up | PRODUCT NAME: TOREMIFENE; REGISTRATION NO/DATE: EU/1/96/004/001 19960215 |
| 0095875 | SPC/GB96/029 | United Kingdom | ⤷ Sign Up | |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
